AcelRx CEO mentioned.

Furthermore, FDA provided clarity on the advancement requirements to register ARX-02 for the broader indication of chronic breakthrough pain in opioid-tolerant patients, where we think that ARX-02 can have an impact on the lives of a broader selection of opioid-tolerant patients. .. AcelRx completes ARX-02 End-of-Phase 2 ending up in FDA for malignancy breakthrough pain management system AcelRx Pharmaceuticals, Inc. FDA reviewed a package predicated on the previously announced positive Phase 2 clinical study results to day for ARX-02 and provided AcelRx with guidance on the Phase 3 program style and NDA requirements. Richard King, AcelRx CEO mentioned, Given this guidance, we have clarity on the development path for ARX-02 in cancer breakthrough discomfort.An initiative led jointly by UC NORTH PARK and the Lawrence Berkeley National Laboratory, Cal-BRAIN is short for California Blueprint for Research to Advance Innovations in Neuroscience. The program was signed into rules in June 2014 and may be the California complement to the federal Human brain Initiative announced by President Barack Obama in 2013. ‘State investment is critical to the advancement of important analysis in California,’ said UC San Diego Chancellor Pradeep K. Khosla. ‘This funding will enable a few of our nation’s most talented and innovative researchers to make discoveries that will transform lives and advantage society for years to come.’ Scientists from all California nonprofit research institutions were eligible to apply for Cal-Mind grants.